Bicara Therapeutics Inc. Common Stock (BCAX) Stock Price, Quote & AI Analysis

Live BCAX stock price, real-time charts, AI-powered trade signals, technical analysis, earnings insights, and market sentiment for Bicara Therapeutics Inc. Common Stock.

TradeVae provides AI-driven analysis and real-time market intelligence for Bicara Therapeutics Inc. Common Stock (BCAX), including price action, technical indicators, earnings performance, analyst sentiment, and short-term trade setups.

BCAX
Bicara Therapeutics Inc. Common Stock
real-time
$0.00 +0.00 (+0.00%)
Open
16.650000
High
17.300000
Low
16.607500
Volume
17,086
VWAP
-
Market Cap
$920,336,760.00
52W Range
$7.80 - $19.71
P/E Ratio
-
EPS
-
Debt/Equity
-
EV/EBITDA
-
Upcoming Earnings
Mar 24, 2026 Q4
Market
EPS Estimate: $-0.6899
Loading chart...

AI Analysis

Explore comprehensive AI-powered analysis including summary insights, bull and bear cases, key risks, and factors to watch.

Loading...

Generating AI analysis...

-
-
-
-

Bicara Therapeutics Inc. Common Stock's fundamentals reflect its scale, profitability, and position within the global technology sector. Key valuation and financial metrics are summarized below, followed by detailed financial statements.

Bicara Therapeutics Inc. Common Stock Overview

Company information

Company Overview

Bicara Therapeutics, Inc. is a clinical-stage biotechnology company and develops biologics engineered to combine the precision of well validated, tumor-targeting antibodies with the power of tumor microenvironment modulators. The company’s bi-functional antibodies are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, offering the potential for synergistic therapeutic impact at the site of the tumor. Its products include BCA101, a first-in-class EGFR/TGF-ß-trap bifunctional antibody in clinical development for multiple tumor types. The company was founded on December 12, 2018 and is headquartered in Boston, MA.

Company Details
Market Cap
$945.75M
Shares Outstanding
54,781,951
Weighted Shares Outstanding
54,781,950
CEO
Claire Mazumdar
Address
116 HUNTINGTON AVENUE SUITE 703, BOSTON, MA, 02116
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
XNAS

Technical Indicators

Key technical analysis metrics and signals

Loading...

Loading technical indicators...

Valuation Metrics

Key valuation ratios and comparisons

Loading...

Loading valuation metrics...

Bicara Therapeutics Inc. Common Stock Earnings & Financial Statements

Earnings Calendar

Upcoming earnings dates and historical surprises

Loading...

Loading earnings calendar...

Financial Statements

Income statements, balance sheets, and cash flow

Loading...

Loading income statements...

Loading...

Loading balance sheets...

Loading...

Loading cash flow statements...